Search Results - stanley+riddell

6 Results

Sort By:

Method of adoptive T cell therapy utilizing notch signaling to enhance efficacy

Notch Activation to Improve Persistence and Efficacy of T Cell Therapies Method of using Notch ligands during culturing to improve the persistence and efficacy of CAR T cell therapies. While CAR T-based cell therapies are promising, the persistence, proliferation, and efficacy of those engineered T cell therapies need to be improved. Additionally,...

Published: 10/14/2024 | Updated: 3/10/2024 | Inventor(s): Irwin Bernstein, Stanley Riddell, Margot Pont

Keywords(s): Immuno Oncology, Target

Category(s): Therapeutic

Markers for identification and sorting of neoantigen specific CD4 T cells from solid tumors

CD4+ T cell markers, compositions, and methods for cancer therapy Markers, methods, and compositions for identifying CD4+ T cells (or T cell receptor genes thereof) with tumor antigen specificity, tumor neoantigen specificity, and/or tumor-infiltrating capacity. While cancer immunotherapies have historically focused on CD8+ T cells, tumor antigen...

Published: 12/5/2023 | Updated: 12/5/2023 | Inventor(s): Joshua Veatch, Stanley Riddell

Keywords(s): Immuno Oncology

Category(s): Cell Therapy

MHC class II restricted T cell receptors targeting mutations in EGFR

MHC class II restricted T cell receptors targeting mutations in EGFR Compositions and methods for targeting EGFR antigens (for e.g., to treat or manage cancer) Activating mutations in EGFR cause a subset of non-small cell lung cancer that occurs preferentially in women and non-smokers. EGFR mutated lung cancer responds to small molecule kinase...

Published: 12/5/2023 | Updated: 12/5/2023 | Inventor(s): Joshua Veatch, Stanley Riddell

Keywords(s): Immuno Oncology

Category(s): Cell Therapy, Therapeutic

Endothelial activation as a biomarker of toxicity after adoptive T cell therapy

Biomarkers Predicting Risk of Cytokine Release Syndrome and Neurotoxicity Following Adoptive T Cell Therapy Risk stratification using serum-derived biomarkers to predict adverse patient responses following adoptive T cell therapies. Few assays are currently available that identify patients who are at risk of developing severe cytokine release...

Published: 2/20/2024 | Updated: 12/3/2020 | Inventor(s): Cameron Turtle, Jose Lopez, W. Conrad Liles, Stanley Riddell, David Maloney, Mark Wurfel, Dominic Chung, Junmei Chen

Keywords(s): Biomarker

Category(s): Diagnostic

Chimeric antigen receptor designs for improved recognition of low-density antigens

CAR Design Improvements for the Recognition of Low-Density Antigens Methods and tools to increase CAR-T cell recognition of tumor cells expressing low density antigens Adoptive transfer of CAR-expressing T cells is an effective cancer therapy for a proportion of individuals with B cell malignancies and multiple myeloma, but efficacy is limited...

Published: 8/28/2024 | Updated: 5/21/2020 | Inventor(s): Alexander Salter, Stanley Riddell, Anusha Rajan

Keywords(s): Immuno Oncology

Category(s): Cell Therapy

A Method For The Treatment Of Obesity Using Immunotherapy With Monoclonal Antibodies, Endogenous T Cells, Or T Cells Modified To Express A Chimeric Antigen Receptor Specific For The Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1)

Immunotherapy for the Treatment of Obesity A method for using immunotherapy to identify, target and eliminate fat cells. Currently, there are no treatments for obesity that directly target and eliminate fat cells (adipocytes). Dr. Stanley Riddell, in collaboration with colleagues at the NIH, have demonstrated that an anti-ROR1 CAR T is...

Published: 11/15/2023 | Updated: 5/17/2017 | Inventor(s): Stanley Riddell, Michael Hudecek, Christoph Rader

Keywords(s): HSC Therapy

Category(s): Cell Therapy, Therapeutic, Gene Therapy